According to the most recently proposed diagnostic criteria for AD, diagnosis of the disease should rely on using in vivo biomarkers of amyloid pathology (decreased Aβ 1-42 or Aβ 1-42/Aβ 1-40 ratio in CSF, or increased tracer retention in amyloid positron emission tomography (PET)) and tau pathology (increased tracer retention in tau PET and increased CSF levels of tTau and pTau181), which allows for an earlier and more accurate diagnosis of the disease [4,5,11,12,13]. Here, MAPT is linked to Alzheimer disease.